MiNK Therapeutics, Inc 8-K, filed Oct 17, 2023
MiNK Therapeutics, Inc. (INKT)
About this 8-K
MiNK Therapeutics, Inc filed this 8-K on October 17, 2023, reporting on events of October 12, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 12, 2023, Dr. John Baldoni sent notice of his resignation as a director at MiNK Therapeutics, Inc. (the "Company"), effective October 31, 2023. Dr. Baldoni cited the Company’s manufacturing advancements and progress, thereby lessening the need for his scientific and technical contributions on the Board of Directors. Dr. Baldoni will advise the Company on an ad hoc basis as a technical advisor. Dr. Baldoni did not step down as a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
Date: |
October 17, 2023 |
By: |
/s/ Jennifer S. Buell, Ph.D. |
|
|
|
Jennifer S. Buell, Ph.D., President and Chief Executive Officer |